# A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

> **NCT02334800** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 28 (actual)

## Conditions studied

- Healthy, Hepatic Insufficiency

## Interventions

- **DRUG:** Palbociclib 75 mg Capsule

## Key facts

- **NCT ID:** NCT02334800
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-31
- **Primary completion:** 2016-10-09
- **Final completion:** 2016-10-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334800, "A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02334800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*